BG104076A - Combined treatment including amplodipin and a statine compound - Google Patents

Combined treatment including amplodipin and a statine compound

Info

Publication number
BG104076A
BG104076A BG104076A BG10407600A BG104076A BG 104076 A BG104076 A BG 104076A BG 104076 A BG104076 A BG 104076A BG 10407600 A BG10407600 A BG 10407600A BG 104076 A BG104076 A BG 104076A
Authority
BG
Bulgaria
Prior art keywords
combinations
pharmaceutically acceptable
patients
amplodipin
statine
Prior art date
Application number
BG104076A
Other languages
Bulgarian (bg)
English (en)
Inventor
Jan Buch
Robert Scott
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG104076(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG104076A publication Critical patent/BG104076A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
BG104076A 1997-08-29 2000-01-13 Combined treatment including amplodipin and a statine compound BG104076A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5755597P 1997-08-29 1997-08-29
PCT/IB1998/001220 WO1999011263A1 (en) 1997-08-29 1998-08-10 Combination therapy comprising amlodipine and a statin compound

Publications (1)

Publication Number Publication Date
BG104076A true BG104076A (en) 2000-09-29

Family

ID=22011309

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104076A BG104076A (en) 1997-08-29 2000-01-13 Combined treatment including amplodipin and a statine compound

Country Status (36)

Country Link
US (1) US20020025981A1 (is)
EP (1) EP1003507A1 (is)
JP (1) JP2001514224A (is)
KR (1) KR20010022385A (is)
CN (1) CN1117566C (is)
AP (1) AP1207A (is)
AR (1) AR017514A1 (is)
AU (1) AU744982B2 (is)
BG (1) BG104076A (is)
BR (1) BR9811558A (is)
CA (1) CA2296726C (is)
CO (1) CO4970726A1 (is)
DZ (1) DZ2600A1 (is)
EA (1) EA002705B1 (is)
GT (1) GT199800134A (is)
HN (1) HN1998000124A (is)
HR (1) HRP980475A2 (is)
HU (1) HUP0003103A3 (is)
ID (1) ID24275A (is)
IL (2) IL133957A0 (is)
IS (1) IS5345A (is)
MA (1) MA26539A1 (is)
NO (1) NO20000999L (is)
NZ (1) NZ502283A (is)
OA (1) OA11289A (is)
PA (1) PA8457201A1 (is)
PE (1) PE106999A1 (is)
PL (1) PL339088A1 (is)
SA (1) SA98190432A (is)
SK (1) SK1392000A3 (is)
TN (1) TNSN98158A1 (is)
TR (1) TR200000562T2 (is)
UY (1) UY25159A1 (is)
WO (1) WO1999011263A1 (is)
YU (1) YU2700A (is)
ZA (1) ZA987843B (is)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40792E1 (en) 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
DK1140184T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
AU2003207431A1 (en) 2002-01-17 2003-09-02 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100742432B1 (ko) 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
JP5330825B2 (ja) 2006-03-29 2013-10-30 興和株式会社 トリグリセリド低下剤及び高インスリン血症改善剤
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023958A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.
WO2009127922A2 (ko) * 2008-02-22 2009-10-22 한올제약 주식회사 심혈관계 질환 치료용 약제학적 제제
WO2009125987A2 (ko) * 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
WO2010008203A2 (ko) * 2008-07-15 2010-01-21 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
CN101804055B (zh) * 2010-04-27 2012-01-25 施慧达药业集团(吉林)有限公司 复方药物制剂
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
TN2017000344A1 (en) * 2015-02-06 2019-01-16 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
EP3706799B8 (en) * 2017-11-10 2025-04-23 Op-T Llc Peptide for preventing, modulating and/or reducing cardiovascular disease
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
CN114727955B (zh) * 2019-11-25 2024-03-26 福多兹制药公司 包含降脂和降血压药物的制剂
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN176897B (is) * 1993-10-29 1996-09-28 Cadila Lab Ltd
DE19539363A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen

Also Published As

Publication number Publication date
SA98190432A (ar) 2005-12-03
CA2296726A1 (en) 1999-03-11
HUP0003103A2 (hu) 2001-01-29
CA2296726C (en) 2004-06-29
CO4970726A1 (es) 2000-11-07
IS5345A (is) 2000-01-14
TR200000562T2 (tr) 2000-08-21
AP1207A (en) 2003-09-20
EA002705B1 (ru) 2002-08-29
ID24275A (id) 2000-07-13
US20020025981A1 (en) 2002-02-28
HN1998000124A (es) 1999-02-09
AU744982B2 (en) 2002-03-07
NZ502283A (en) 2002-05-31
AR017514A1 (es) 2001-09-12
ZA987843B (en) 2000-02-28
MA26539A1 (fr) 2004-12-20
NO20000999D0 (no) 2000-02-28
JP2001514224A (ja) 2001-09-11
WO1999011263A1 (en) 1999-03-11
OA11289A (en) 2003-08-25
PE106999A1 (es) 1999-11-06
UY25159A1 (es) 2000-12-29
IL133957A (en) 2006-06-11
NO20000999L (no) 2000-02-28
PA8457201A1 (es) 2000-05-24
YU2700A (sh) 2002-06-19
CN1117566C (zh) 2003-08-13
GT199800134A (es) 2000-02-08
CN1268054A (zh) 2000-09-27
EP1003507A1 (en) 2000-05-31
HK1029530A1 (en) 2001-04-06
EA200000013A1 (ru) 2000-08-28
HRP980475A2 (en) 1999-06-30
HUP0003103A3 (en) 2002-03-28
KR20010022385A (ko) 2001-03-15
DZ2600A1 (fr) 2003-03-01
AU8458598A (en) 1999-03-22
AP9801333A0 (en) 1998-09-30
IL133957A0 (en) 2001-04-30
PL339088A1 (en) 2000-12-04
BR9811558A (pt) 2000-08-22
SK1392000A3 (en) 2000-08-14
TNSN98158A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
BG104177A (en) Amlodipin- and atorvastatin-containing therapeutical combinations
CA2296726A1 (en) Combination therapy
EA200300155A1 (ru) Терапевтическая комбинация ингибитора сетр и аторвастатина
CA2210889A1 (en) Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
WO1995017876A3 (en) 2,4-disulphophenyl butylnitrone, its salts, and their use as pharmaceutical spintraps
CA2218555A1 (en) Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
MY121008A (en) Combination therapy comprising atorvastatin and an antihypertensive agent.
EP2573079A3 (en) Benzimidazole quinolinones and uses thereof
NO974163L (no) Ester av 5-aminolevulinsyre som fotosensibiliserings-middel i fotokjemoterapi
CA2375225A1 (en) Mutual salt of amlodipine and atorvastatin
CO5570109A1 (es) Compuestos de dihidropirimidina heterociclicos
ZA9711606B (en) Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
AU3191995A (en) Fused pyridazine compound
CA2028746A1 (en) Pharmaceutical compositions and methods for treating the symptoms of overindulgence
EP1559717A3 (en) Oxabispidine compounds useful in the treatment of cardiac arrythmias
CY1107763T1 (el) Εναντιομερεις ενωσεις για την αγωγη καρδιακων αρρυθμιων και μεθοδοι χρησεως
CA2146238A1 (en) Novel mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace
BR9915610A (pt) Preparações farmacêuticas combinadas
CA2233315A1 (en) Pharmaceutical compositions containing hydroximic acid derivatives
CA2370244A1 (en) Piperidine derivatives
CA2375372A1 (en) Mutual prodrugs of amlodipine and atorvastatin
MX9707683A (es) Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
CA2215234A1 (en) Composition containing amlodipine, or its salt and an ace inhibitor
DK1035859T3 (da) Anvendelse af phospholipidkomplekser fra ekstrakter af Vitis vinifera som anti-atherosklerotiske midler